Swedish Orphan Biovitrum AB (publ) (SOBI) Plunged -0.74% on Nov 19

November 19, 2017 - By Richard Conner

Shares of Swedish Orphan Biovitrum AB (publ) (STO:SOBI) last traded at 120.1, representing a move of -0.74%, or -0.9 per share, on volume of 549,354 shares. After opening the trading day at 120, shares of Swedish Orphan Biovitrum AB (publ) traded in a close range. Swedish Orphan Biovitrum AB (publ) currently has a total float of 269.12 million shares and on average sees 639,262 shares exchange hands each day. The stock now has a 52-week low of 92.9 and high of 143.8.

The Swedish Equity Market

Sweden is known around the world for a lot of global brands. However, there is so much beyond those that Sweden is rarely linked to or acknowledged for.

What most people don’t know is that Sweden is also home to one of the best economies in all of Europe. With good corporate governance and a healthy trade and commerce environment, the Swedish economy is immensely growing to become more and more influential regionally and globally. It influence spread on the companies at the market like Swedish Orphan Biovitrum AB (publ). Through time, it has been established that Sweden is one of the most valuable contributors to the growth of the European economy.

The Stock Exchange

In Sweden, the Stockholm Stock Exchange or Nasdaq Stockholm is the main stock exchange situated in Frihamnen, Stockholm. Like the other stock exchanges in Nordic nations such as Norway and Iceland, it is owned and operated by Nasdaq, Inc. since 2008. These Nasdaq Nordic stock exchanges include the Tallinn Stock Exchange or Nasdaq Baltic; the Riga Stock Exchange or Nasdaq Baltic; the Iceland Stock Exchange or Nasdaq Iceland; the Helsinki Stock Exchange or Nasdaq Helsinki; the Copenhagen Stock Exchange or Nasdaq Copenhagen; and the Armenia Stock Exchange or Nasdaq OMX Armenia.

The Nasdaq Stockholm has been around since 1863. Until May 1990, it had operated at the Stockholm Stock Exchange Building using a floor trading system. It is in June 1990 that electronic trading system had arrived in the country. It brings improvements with each new year to the work of the market, helping Swedish Orphan Biovitrum AB (publ) to stay there.

Regular trading on the Nasdaq Stockholm opens at 9:00 a.m. and closes at 5:00 p.m. Today, more than 300 stocks are listed on the Nasdaq Stockholm. Its total market valuation is currently at $1.26 trillion.

The Index

The benchmark index in Sweden is the OMX Stockholm 30 (OMXS30), which is a market-capitalization-weighted index that tracks the top 30 stocks listed on the Nasdaq Stockholm. It uses the base value of 125 points— the base date being September 1986.

The OMXS30 is semi-annually rebalanced in order to ensure proper and accurate indication of the Swedish economy. Every rebalancing period, old stocks can be dropped from it and new ones can be added— largely depending on different factors and overall performance in the equity market.

The three largest sectors in the OMXS30 include Industrials, Financials, and Consumer Services.

The OMXS30 had posted its all-time low of 98.96 points, which is widely attributed to Black Monday, in November 1987. During the last few months of the year 1987, equity markets around the world had tumbled, which is an event now commonly dubbed as Black Monday. The meltdown had begun in Hong Kong and quickly spread like a wildfire worldwide.

Nonetheless, the OMXS30 had eventually banked gains, posting its all-time high of 1,719.93 in April 2015. Swedish Orphan Biovitrum AB (publ) also received the increase.

It is a general truth that the best way to bet on a country’s growth potentials and long-term prospects is to penetrate its equity market. Consequently, the best way to bank on the growth of the Swedish economy and to maximize the opportunities in the nation is to invest on Nasdaq Stockholm stocks.

More notable recent Swedish Orphan Biovitrum AB (publ) (STO:SOBI) news were published by: Businesswire.com which released: “Swedish Orphan Biovitrum AB: European Commission Grants SOBI003 Orphan …” on October 19, 2016, also Prnewswire.com with their article: “Auxilium Pharmaceuticals, Inc. And Swedish Orphan Biovitrum AB (publ) Enter A …” published on July 16, 2013, Businesswire.com published: “Swedish Orphan Biovitrum AB: Elocta® obtains reimbursement in UK, Italy and …” on September 21, 2016. More interesting news about Swedish Orphan Biovitrum AB (publ) (STO:SOBI) were released by: Businesswire.com and their article: “Swedish Orphan Biovitrum AB: Health Canada Validates Orfadin® Capsule Filing” published on July 14, 2016 as well as Prnewswire.com‘s news article titled: “Swedish Orphan Biovitrum AB – Orfadin® Capsules Approved in the Kingdom of …” with publication date: May 17, 2017.

Swedish Orphan Biovitrum publ AB is a Sweden pharmaceutical company. The company has market cap of $32.73 billion. The Firm develops, makes and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. It has a 37.51 P/E ratio. The Company’s product portfolio is divided into three business divisions: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment.